{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T09:42:25Z","timestamp":1698658945096},"reference-count":58,"publisher":"Hindawi Limited","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":2069,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,1]]},"DOI":"10.1111\/j.1600-0404.2009.01317.x","type":"journal-article","created":{"date-parts":[[2010,1,20]],"date-time":"2010-01-20T03:40:24Z","timestamp":1263958824000},"source":"Crossref","is-referenced-by-count":3,"title":["Can we face the challenge of expanding use of intravenous immunoglobulin in neurology?"],"prefix":"10.1155","author":[{"given":"I.","family":"Elovaara","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Hietaharju","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"98","reference":[{"key":"10.1111\/j.1600-0404.2009.01317.x-BIB1","first-page":"81","article-title":"High-dose intravenous gammaglobulin therapy of refractory, in particular idiopathic thrombocytopenia in childhood","volume":"36","author":"Imbach","year":"1981","journal-title":"Helv Pediatr Acta"},{"key":"10.1111\/j.1600-0404.2009.01317.x-BIB2","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S0140-6736(81)90810-2","article-title":"High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura","volume":"2","author":"Schmidt","year":"1981","journal-title":"Lancet"},{"key":"10.1111\/j.1600-0404.2009.01317.x-BIB3","first-page":"69","article-title":"Ein klinisches Modell zur Regulation der Humoralen. Immunantwort: Infusion therapie. Beitr Infusionther","volume":"9","author":"Fateh-Moghadam","year":"1982","journal-title":"Klin Ernahr"},{"key":"10.1111\/j.1600-0404.2009.01317.x-BIB4","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/0022-510X(85)90173-X","article-title":"Plasma and gamma globulin infusion in chronic inflammatory demyelinating polyneuropathy","volume":"70","author":"Vermeulen","year":"1985","journal-title":"J Neurol Sci"},{"key":"10.1111\/j.1600-0404.2009.01317.x-BIB5","first-page":"719","article-title":"Initial experiences in the use of intravenous immunoglobulins in Guillain-Barr\u00e9-Strohl syndrome","volume":"9","author":"Ceccarelli","year":"1987","journal-title":"Pediatr Med Chir"},{"key":"10.1111\/j.1600-0404.2009.01317.x-BIB6","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1056\/NEJMra993360","article-title":"Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin","volume":"345","author":"Kazatchkine","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1600-0404.2009.01317.x-BIB7","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.intimp.2005.11.013","article-title":"Intravenous immunoglobulin in autoimmune disorders: an insight into the immunoregulatory mechanisms","volume":"6","author":"Bayry","year":"2006","journal-title":"Int Immunopharmacol"},{"key":"10.1111\/j.1600-0404.2009.01317.x-BIB8","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/j.1600-065X.1994.tb00855.x","article-title":"Pooled human IgG modulates cytokine production in lymphocytes and monocytes","volume":"139","author":"Andersson","year":"1994","journal-title":"Immunol Rev"},{"key":"10.1111\/j.1600-0404.2009.01317.x-BIB9","doi-asserted-by":"crossref","first-page":"721","DOI":"10.7326\/0003-4819-126-9-199705010-00008","article-title":"Intravenous immune globulin therapy for neurologic diseases","volume":"126","author":"Dalakas","year":"1997","journal-title":"Ann Intern Med"},{"key":"10.1111\/j.1600-0404.2009.01317.x-BIB10","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1126\/science.1129594","article-title":"Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation","volume":"313","author":"Kaneko","year":"2006","journal-title":"Science"},{"key":"10.1111\/j.1600-0404.2009.01317.x-BIB11","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S1474-4422(08)70215-1","article-title":"Clinical features, pathogenesis, and treatment of Guillain-Barr\u00e9 syndrome","volume":"7","author":"van Doorn","year":"2008","journal-title":"Lancet Neurol"},{"key":"10.1111\/j.1600-0404.2009.01317.x-BIB12","first-page":"CD004429","article-title":"Intravenous immunoglobulin for multifocal motor neuropathy","author":"van Schaik","year":"2005","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1111\/j.1600-0404.2009.01317.x-BIB13","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/S0165-5728(01)00243-0","article-title":"Polyspecific immunoglobulins (IVIg) suppress proliferation of human (auto)antigen-specific T cells without inducing apoptosis","volume":"114","author":"Aktas","year":"2001","journal-title":"J Neuroimmunol"},{"key":"10.1111\/j.1600-0404.2009.01317.x-BIB14","first-page":"5","article-title":"Intravenous immunoglobulins in MS","volume":"12(1)","author":"Stangel","year":"2005","journal-title":"Int MS J"},{"key":"10.1111\/j.1600-0404.2009.01317.x-BIB15","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.jneuroim.2006.04.023","article-title":"IVIg attenuates T cell-mediated killing of human neurons","volume":"177","author":"Janke","year":"2006","journal-title":"J Neuroimmunol"},{"key":"10.1111\/j.1600-0404.2009.01317.x-BIB16","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.jneuroim.2009.01.014","article-title":"Therapeutic activities of intravenous immunoglobulins in multiple sclerosis involve modulation of chemokine expression","volume":"209","author":"Pigard","year":"2009","journal-title":"J Neuroimmunol"},{"key":"10.1111\/j.1600-0404.2009.01317.x-BIB17","first-page":"CD002063","article-title":"Intravenous immunoglobulin for Guillain-Barr\u00e9 syndrome","author":"Hughes","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1111\/j.1600-0404.2009.01317.x-BIB18","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1212\/01.wnl.0000258673.31824.61","article-title":"Intravenous immunoglobulin therapy for Miller Fisher syndrome","volume":"68","author":"Mori","year":"2007","journal-title":"Neurology"},{"key":"10.1111\/j.1600-0404.2009.01317.x-BIB19","first-page":"CD001797","article-title":"Intravenous immunoglobulin for chronic inflammatory demyelinating polyneuropathy","volume":"21","author":"Eftimov","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1111\/j.1600-0404.2009.01317.x-BIB20","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/S1474-4422(07)70329-0","article-title":"Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial","volume":"7","author":"Hughes","year":"2008","journal-title":"Lancet Neurol"},{"key":"10.1111\/j.1600-0404.2009.01317.x-BIB21","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1586\/ern.09.30","article-title":"Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy: the ICE trial","volume":"9","author":"Hughes","year":"2009","journal-title":"Expert Rev Neurother"},{"key":"10.1111\/j.1600-0404.2009.01317.x-BIB22","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1111\/j.1468-1331.2008.02246.x","article-title":"EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases","volume":"15","author":"Elovaara","year":"2008","journal-title":"Eur J Neurol"},{"key":"10.1111\/j.1600-0404.2009.01317.x-BIB23","first-page":"CD003280","article-title":"Cytotoxic drugs and interferons for chronic inflammatory demyelinating polyradiculoneuropathy","author":"Hughes","year":"2004","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1111\/j.1600-0404.2009.01317.x-BIB24","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1136\/jnnp.2007.121756","article-title":"Intravenous immunoglobulin as short- and long-term therapy of multifocal motor neuropathy: a retrospective study of response to IVIG and of its predictive criteria in 40 patients","volume":"79","author":"L\u00e9ger","year":"2008","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1111\/j.1600-0404.2009.01317.x-BIB25","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1212\/01.WNL.0000110185.23464.A1","article-title":"How long is IVIG effective in multifocal motor neuropathy?","volume":"62","author":"Terenghi","year":"2004","journal-title":"Neurology"},{"key":"10.1111\/j.1600-0404.2009.01317.x-BIB26","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1093\/brain\/121.3.421","article-title":"The long-term effect of intravenous immunoglobulin treatment in multifocal motor neuropathy","volume":"121","author":"van den Berg","year":"1998","journal-title":"Brain"},{"key":"10.1111\/j.1600-0404.2009.01317.x-BIB27","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1093\/brain\/awm144","article-title":"Mycophenolate mofetil as adjunctive therapy for MMN patients: a randomized, controlled trial","volume":"130","author":"Piepers","year":"2007","journal-title":"Brain"},{"key":"10.1111\/j.1600-0404.2009.01317.x-BIB28","first-page":"CD002277","article-title":"Intravenous immunoglobulin for myasthenia gravis","author":"Gajdos","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1111\/j.1600-0404.2009.01317.x-BIB29","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1212\/01.wnl.0000256698.69121.45","article-title":"IV immunoglobulin in patients with myasthenia gravis. A randomized controlled trial","volume":"68","author":"Zinman","year":"2007","journal-title":"Neurology"},{"issue":"Suppl. 1","key":"10.1111\/j.1600-0404.2009.01317.x-BIB30","doi-asserted-by":"crossref","first-page":"S57","DOI":"10.1016\/j.tmrv.2007.01.002","article-title":"Guidelines on the use of intravenous immune globulin for neurologic conditions","volume":"21","author":"Feasby","year":"2007","journal-title":"Transfus Med Rev"},{"key":"10.1111\/j.1600-0404.2009.01317.x-BIB31","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1001\/archneur.62.11.1689","article-title":"Treatment of myasthenia gravis exacerbation with intravenous immunoglobulin: a randomized double-blind clinical trial","volume":"62","author":"Gajdos","year":"2005","journal-title":"Arch Neurol"},{"key":"10.1111\/j.1600-0404.2009.01317.x-BIB32","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1212\/01.wnl.0000318281.98220.6f","article-title":"Intravenous immunoglobulin in relapsing-remitting multiple sclerosis. A dose-finding trial","volume":"71","author":"Fazekas","year":"2008","journal-title":"Neurology"},{"key":"10.1111\/j.1600-0404.2009.01317.x-BIB33","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1111\/j.1468-1331.2008.02258.x","article-title":"Treatment of corticosteroid refractory optic neuritis in multiple sclerosis patients with intravenous immunoglobulin","volume":"15","author":"Tselis","year":"2008","journal-title":"Eur J Neurol"},{"key":"10.1111\/j.1600-0404.2009.01317.x-BIB34","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1111\/j.1468-1331.2008.02257.x","article-title":"Winning combination: the additive\/synergistic benefits of IVIg in corticosteroid refractory optic neuritis","volume":"15","author":"Achiron","year":"2008","journal-title":"Eur J Neurol"},{"key":"10.1111\/j.1600-0404.2009.01317.x-BIB35","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S0140-6736(04)17101-8","article-title":"Intravenous immunoglobulin in secondary progressive multiple sclerosis: randomised placebo-controlled trial","volume":"364","author":"Hommes","year":"2004","journal-title":"Lancet"},{"key":"10.1111\/j.1600-0404.2009.01317.x-BIB36","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1177\/1352458507078400","article-title":"Intravenous immunoglobulin in primary and secondary chronic progressive multiple sclerosis: a randomized placebo controlled multicentre study","volume":"13","author":"P\u00f6hlau","year":"2007","journal-title":"Mult Scler"},{"key":"10.1111\/j.1600-0404.2009.01317.x-BIB37","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1001\/archneur.61.10.1515","article-title":"Intravenous immunoglobulin treatment following the first demyelinating event suggestive of multiple sclerosis: a randomized, double-blind, placebo-controlled trial","volume":"61","author":"Achiron","year":"2004","journal-title":"Arch Neurol"},{"issue":"Suppl. 2","key":"10.1111\/j.1600-0404.2009.01317.x-BIB38","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1177\/135245850000602S05","article-title":"High dose IVIG in the post partum period for prevention of exacerbations in MS","volume":"6","author":"Haas","year":"2000","journal-title":"Mult Scler"},{"key":"10.1111\/j.1600-0404.2009.01317.x-BIB39","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1177\/1352458506075654","article-title":"A dose comparison study of IVIG in postpartum relapsing-remitting multiple sclerosis","volume":"13","author":"Haas","year":"2007","journal-title":"Mult Scler"},{"key":"10.1111\/j.1600-0404.2009.01317.x-BIB40","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/BF00878527","article-title":"Intravenous immunoglobulin treatment in the prevention of childbirth-associated acute exacerbations in multiple sclerosis: a pilot study","volume":"243","author":"Achiron","year":"1996","journal-title":"J Neurol"},{"key":"10.1111\/j.1600-0404.2009.01317.x-BIB41","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1056\/NEJM199312303292704","article-title":"A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis","volume":"329","author":"Dalakas","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1600-0404.2009.01317.x-BIB42","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1002\/art.10053","article-title":"Results and long-term follow up of intravenous immunoglobulin infusions in chronic, refractory polymyositis: an open study with thirty-five adult patients","volume":"46","author":"Cherin","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1111\/j.1600-0404.2009.01317.x-BIB43","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1056\/NEJMoa01167","article-title":"High-dose intravenous immunoglobulin for Stiff-person syndrome","volume":"345","author":"Dalakas","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1600-0404.2009.01317.x-BIB44","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/ncpneuro0376","article-title":"Drug insight: the use of intravenous immunoglobulin in neurology-therapeutic considerations and practical issues","volume":"3","author":"Gold","year":"2007","journal-title":"Nat Clin Pract Neurol"},{"key":"10.1111\/j.1600-0404.2009.01317.x-BIB45","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.jocn.2006.03.020","article-title":"Pharmacoeconomics of therapy for Guillain-Barr\u00e9 syndrome: plasma exchange and intravenous immunoglobulin","volume":"14","author":"Tsai","year":"2007","journal-title":"J Clin Neurosci"},{"key":"10.1111\/j.1600-0404.2009.01317.x-BIB46","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1046\/j.1351-5101.2003.00701.x","article-title":"Cost-utility analysis of intravenous immunoglobulin and prednisolone for chronic inflammatory demyelinating polyradiculoneuropathy","volume":"10","author":"McCrone","year":"2003","journal-title":"Eur J Neurol"},{"key":"10.1111\/j.1600-0404.2009.01317.x-BIB47","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1212\/WNL.0b013e3181a0fd80","article-title":"Health-related quality-of-life improvements in CIDP with immune globulin IV 10%. The ICE study","volume":"72","author":"Merkies","year":"2009","journal-title":"Neurology"},{"key":"10.1111\/j.1600-0404.2009.01317.x-BIB48","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/S1474-4422(08)70299-0","article-title":"Randomised controlled trial of methotrexate for chronic inflammatory demyelinating polyradiculoneuropathy (RMC trial): a pilot, multicentre study","volume":"8","author":"RMC Trial Group","year":"2009","journal-title":"Lancet Neurol"},{"key":"10.1111\/j.1600-0404.2009.01317.x-BIB49","doi-asserted-by":"crossref","first-page":"55","DOI":"10.7326\/0003-4819-93-1-55","article-title":"Immunoglobulin replacement by slow subcutaneous infusion","volume":"98","author":"Berger","year":"1980","journal-title":"Ann Intern Med"},{"key":"10.1111\/j.1600-0404.2009.01317.x-BIB50","doi-asserted-by":"crossref","first-page":"105","DOI":"10.2165\/00063030-200721020-00005","article-title":"Immunoglobulin treatment for primary antibody deficiencies: advantages of the subcutaneous route","volume":"21","author":"Gardulf","year":"2007","journal-title":"BioDrugs"},{"key":"10.1111\/j.1600-0404.2009.01317.x-BIB51","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/j.iac.2008.07.002","article-title":"Subcutaneous administration of IgG","volume":"28","author":"Berger","year":"2008","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1111\/j.1600-0404.2009.01317.x-BIB52","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1007\/s00415-006-0258-0","article-title":"Subcutaneous self-infusions of immunoglobulins as a potential therapeutic regimen in immune-mediated neuropathies","volume":"253","author":"K\u00f6ller","year":"2006","journal-title":"J Neurol"},{"key":"10.1111\/j.1600-0404.2009.01317.x-BIB53","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1002\/mus.20909","article-title":"Subcutaneous immunoglobulin infusion: a new therapeutic option in chronic inflammatory demyelinating polyneuropathy","volume":"37","author":"Lee","year":"2008","journal-title":"Muscle Nerve"},{"key":"10.1111\/j.1600-0404.2009.01317.x-BIB54","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1111\/j.1468-1331.2009.02568.x","article-title":"Subcutaneous versus intravenous immunoglobulin in multifocal motor neuropathy: a randomized, single-blinded cross-over trial","volume":"16","author":"Harbo","year":"2009","journal-title":"Eur J Neurol"},{"key":"10.1111\/j.1600-0404.2009.01317.x-BIB55","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/j.1529-8027.2009.00218.x","article-title":"Subcutaneous immunoglobulin therapy for multifocal motor neuropathy","volume":"14","author":"Eftimof","year":"2009","journal-title":"J Peripher Nerv Syst"},{"key":"10.1111\/j.1600-0404.2009.01317.x-BIB56","first-page":"253","article-title":"Human antibodies against amyloid beta peptide: a potential treatment for Alzheimer\u2019s disease","volume":"52","author":"Dodel","year":"2002","journal-title":"Neurology"},{"key":"10.1111\/j.1600-0404.2009.01317.x-BIB57","first-page":"79","article-title":"Intravenous immunoglobulin and Alzheimer\u2019s disease immunotherapy","volume":"9","author":"Solomon","year":"2007","journal-title":"Curr Opin Mol Ther"},{"key":"10.1111\/j.1600-0404.2009.01317.x-BIB58","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1016\/j.neurobiolaging.2007.12.021","article-title":"18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease","volume":"11","author":"Relkin","year":"2009","journal-title":"Neurobiol Aging"}],"container-title":["Acta Neurologica Scandinavica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1600-0404.2009.01317.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1600-0404.2009.01317.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T12:48:41Z","timestamp":1671540521000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1600-0404.2009.01317.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,1]]},"references-count":58,"URL":"https:\/\/doi.org\/10.1111\/j.1600-0404.2009.01317.x","relation":{},"ISSN":["0001-6314","1600-0404"],"issn-type":[{"value":"0001-6314","type":"print"},{"value":"1600-0404","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,1]]}}}